A Novel Proteomics Technology for Protein Farnesylation
蛋白质法呢基化的新型蛋白质组学技术
基本信息
- 批准号:6785160
- 负责人:
- 金额:$ 14.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-06-07 至 2006-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The identification and characterization of changes in the level of farnesylated proteins in response to the treatment of farnesyltransferase inhibitors (FTIs), a newly introduced family of antitumor agents currently undergoing clinical evaluation, represents a major scientific challenge. Extant proteomics methods are limited to quantifying a few thousands of the most abundant proteins and, therefore, are unsuitable for the targeted profiling of less abundant farnesylated expression. The major goal of this application is to develop and validate a powerful technology, Tagging via Azido Substrate (TAS), for the efficient isolation of farnesylated proteins. This technology will then be applied to the proteomics analysis of farnesylated proteins in physiologically relevant models. The TAS technology involves the introduction of a synthetic azide-modified farnesyl substrate, either farnesyl azide diphosphate (FPP-azide) or farnesyl azide alcohol (F-azide-OH), which replaces the natural substrate during cellular protein farnesylation. The resulting farnesyl-azide (F-azide)-modified proteins will be affinity-purified through an azide-specific conjugation reaction (Staudinger reaction) using a phosphine capture reagent linked to photo-cleavable beads, which can then be released by UV light-induced photo-cleavage. Since affinity purification relies on covalent bonding resulting from a specific conjugation reaction between an azide and phosphine capture reagent, other proteins without the F-azide modification can be effectively removed by thorough washing. Thus, the TAS technology will allow farnesylated proteins to be isolated with high yield, high specificity, and low contamination.
The initial focus of the R21 portion of this proposal is on the development of TAS technology and its application to the isolation of farnesylated proteins. These studies will be extended subsequently to geranylgeranylated proteins. The R33 proposal will aim at applications of the TAS technology to the identification of novel FTI targets. These studies will provide fundamental information for the understanding of molecular mechanisms of FTI functions and are likely to identify novel targets for antitumor drug design.
描述(由申请方提供):法尼基转移酶抑制剂(FTIs)(一种新引入的抗肿瘤药物家族,目前正在进行临床评价)治疗后法尼基化蛋白水平变化的鉴别和表征代表了一项重大科学挑战。现存的蛋白质组学方法仅限于定量数千种最丰富的蛋白质,因此不适合于对丰度较低的法尼基化表达进行靶向分析。本申请的主要目标是开发和验证一种强大的技术,通过叠氮基底物(TAS)标记,用于有效分离法尼基化蛋白质。该技术将应用于生理相关模型中法尼基化蛋白质的蛋白质组学分析。 TAS技术涉及引入合成的叠氮化物修饰的法呢基底物,法呢基叠氮二磷酸(FPP-叠氮化物)或法呢基叠氮醇(F-叠氮化物-OH),其在细胞蛋白法呢基化期间替代天然底物。所得的法尼基-叠氮化物(F-叠氮化物)-修饰的蛋白质将通过叠氮化物特异性缀合反应(施陶丁格反应)使用连接至光可裂解珠的膦捕获试剂进行亲和纯化,所述光可裂解珠然后可以通过UV光诱导的光裂解释放。由于亲和纯化依赖于由叠氮化物和膦捕获试剂之间的特异性缀合反应产生的共价键合,因此可以通过彻底洗涤有效地去除没有F-叠氮化物修饰的其他蛋白质。因此,TAS技术将允许以高产率、高特异性和低污染分离法尼基化蛋白质。
该提案的R21部分的最初重点是TAS技术的开发及其在分离法尼基化蛋白质中的应用。这些研究将随后扩展到香叶基香叶基化蛋白质。R33提案旨在将TAS技术应用于识别新的FTI目标。这些研究将为理解FTI功能的分子机制提供基础信息,并可能为抗肿瘤药物设计确定新的靶点。
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software.
- DOI:10.1021/pr8005155
- 发表时间:2009-02
- 期刊:
- 影响因子:4.4
- 作者:Zhang K;Chen Y;Zhang Z;Zhao Y
- 通讯作者:Zhao Y
Unbiased proteomic screen for binding proteins to modified lysines on histone H3.
- DOI:10.1002/pmic.200800600
- 发表时间:2009-05
- 期刊:
- 影响因子:3.4
- 作者:Chan, Doug W.;Wang, Yi;Wu, Meng;Wong, Jiemin;Qin, Jun;Zhao, Yingming
- 通讯作者:Zhao, Yingming
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YINGMING ZHAO其他文献
YINGMING ZHAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YINGMING ZHAO', 18)}}的其他基金
Systematic screening for new histone marks and studying their epigenetic function
系统筛选新组蛋白标记并研究其表观遗传功能
- 批准号:
10579280 - 财政年份:2020
- 资助金额:
$ 14.04万 - 项目类别:
Systematic screening for new histone marks and studying their epigenetic function
系统筛选新组蛋白标记并研究其表观遗传功能
- 批准号:
10401345 - 财政年份:2020
- 资助金额:
$ 14.04万 - 项目类别:
Systems-wide analysis of histone lysine 2-hydroxyisobutyrylation pathway
组蛋白赖氨酸 2-羟基异丁酰化途径的全系统分析
- 批准号:
9458207 - 财政年份:2016
- 资助金额:
$ 14.04万 - 项目类别:
APPLICATION OF PTMAP2 FOR PROTEIN POSTTRANSLATIONAL MODIFICATION ANALYSIS
PTMAP2 在蛋白质翻译后修饰分析中的应用
- 批准号:
8364316 - 财政年份:2011
- 资助金额:
$ 14.04万 - 项目类别:
APPLICATION OF PTMAP2 FOR PROTEIN POSTTRANSLATIONAL MODIFICATION ANALYSIS
PTMAP2 在蛋白质翻译后修饰分析中的应用
- 批准号:
8171932 - 财政年份:2010
- 资助金额:
$ 14.04万 - 项目类别:
DEVELOPMENT OF PTMAP20 FOR GENOME-WIDE PROTEIN POSTTRANSLATIONAL MODIFICATION
用于全基因组蛋白质翻译后修饰的 PTMAP20 的开发
- 批准号:
8171905 - 财政年份:2010
- 资助金额:
$ 14.04万 - 项目类别:
DEVELOPMENT OF PTMAP20 FOR GENOME-WIDE PROTEIN POSTTRANSLATIONAL MODIFICATION
用于全基因组蛋白质翻译后修饰的 PTMAP20 的开发
- 批准号:
7956366 - 财政年份:2009
- 资助金额:
$ 14.04万 - 项目类别:
相似海外基金
Rheb GTPase as chemotherapeutic target for brain tumors
Rheb GTPase 作为脑肿瘤化疗靶点
- 批准号:
7052093 - 财政年份:2005
- 资助金额:
$ 14.04万 - 项目类别:
Rheb GTPase as chemotherapeutic target for brain tumors
Rheb GTPase 作为脑肿瘤化疗靶点
- 批准号:
6921056 - 财政年份:2005
- 资助金额:
$ 14.04万 - 项目类别:
Protein prenylation, oncogenesis and novel therapeutics
蛋白质异戊二烯化、肿瘤发生和新疗法
- 批准号:
6948887 - 财政年份:2004
- 资助金额:
$ 14.04万 - 项目类别:
Protein prenylation, oncogenesis and novel therapeutics
蛋白质异戊二烯化、肿瘤发生和新疗法
- 批准号:
6817729 - 财政年份:2004
- 资助金额:
$ 14.04万 - 项目类别:
Protein prenylation, oncogenesis and novel therapeutics
蛋白质异戊二烯化、肿瘤发生和新疗法
- 批准号:
7114284 - 财政年份:2004
- 资助金额:
$ 14.04万 - 项目类别: